The initial results of AURORA were announced at the ESMO Breast Cancer Congress in Berlin, Germany, by Dr Philippe Aftimos, Co-Principal Investigator of the programme and Clinical Trials Development Leader at the Jules Bordet Institute in Brussels, Belgium.
He presented the results for the first 381 patients included out of a planned total of 1,000. The researchers have identified molecular alterations present in excess in metastases that may be correlated with the spread of cancer and increased resistance to standard treatments.
Read the full press release by BIG.
GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440